Imidazoline I(2) receptor density increases with the malignancy of human gliomas

J Neurol Neurosurg Psychiatry. 2004 May;75(5):785-7. doi: 10.1136/jnnp.2003.020446.

Abstract

Background: Current glioma grading schemes are limited by subjective histological criteria. Imidazoline I(2) receptors are principally expressed on glial cells.

Objective: To investigate the feasibility of using the measurement of imidazoline I(2) receptor expression to differentiate glial tumours from other types of brain tumours and for grading the different gliomas.

Methods: The specific binding of [(3)H]idazoxan to imidazoline I(2) receptors was measured in homogenates from human gliomas of different grades.

Results: The density of imidazoline I(2) receptors was significantly greater in the three types of malignant glial tumours than in postmortem control brain or non-glial tumours. The increase in density correlated with the malignancy grade of the gliomas. No significant differences in affinity values were observed.

Conclusion: These results suggest that the density of imidazoline I(2) receptors may be a useful radioligand parameter for the differentiation of glial tumours from other types of brain tumours and for grading the different gliomas.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Binding Sites
  • Brain Neoplasms / metabolism*
  • Brain Neoplasms / pathology*
  • Cell Count
  • Feasibility Studies
  • Glial Fibrillary Acidic Protein / metabolism
  • Glioma / classification
  • Glioma / metabolism*
  • Glioma / pathology*
  • Humans
  • Idazoxan / metabolism
  • Imidazoline Receptors
  • Neoplasm Staging
  • Receptors, Drug / metabolism*

Substances

  • Glial Fibrillary Acidic Protein
  • Imidazoline Receptors
  • Receptors, Drug
  • Idazoxan